Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q56091164)
Watch
English
Thalidomide
scientific article published in The Lancet
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
review article
1 reference
stated in
Europe PubMed Central
title
Thalidomide
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
main subject
thalidomide
0 references
author name string
Michael E Franks
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
Gordon R Macpherson
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
William D Figg
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
language of work or name
English
0 references
publication date
1 May 2004
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
volume
363
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
page(s)
1802-1811
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
issue
9423
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
cites work
Thalidomide is an inhibitor of angiogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the treatment of leprosy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide update: regulatory aspects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A short history of thalidomide embryopathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in cancer: potential uses and limitations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanism of action in thalidomide teratogenesis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Theoretical basis for the activity of thalidomide.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Novel therapies for multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide for chronic sarcoidosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Update on therapy--thalidomide in the treatment of lupus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide for systemic lupus erythematosus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in Behçet's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of Behçet's disease with thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide: emerging role in cancer medicine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in dermatology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of thalidomide in AIDS-related Kaposi's sarcoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Potential novel uses of thalidomide: focus on palliative care
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide for the treatment of AIDS-associated wasting
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New therapies for heart failure: is thalidomide the answer?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor activity of thalidomide in refractory multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the management of multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of a low dose of thalidomide in advanced multiple myeloma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the treatment of relapsed multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in refractory and relapsing multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide and dexamethasone combination for refractory multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide and dexamethasone for resistant multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in the treatment of multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as initial therapy for early-stage myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of Waldenstrom's macroglobulinemia with thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in agnogenic and secondary myelofibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide treatment in myelofibrosis with myeloid metaplasia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Current role of thalidomide in cancer treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cancer statistics, 2003.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CLINICAL EXPERIENCES WITH THALIDOMIDE IN PATIENTS WITH CANCER
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of thalidomide for patients with advanced renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The treatment of advanced renal cell cancer with high-dose oral thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of thalidomide in renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II study of thalidomide in advanced metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide therapy for renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide as an anti-angiogenic agent in relapsed gliomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of thalidomide on gastrointestinal toxic effects of irinotecan
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide in patients with cachexia due to terminal cancer: preliminary report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide for distressing night sweats in advanced malignant disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II evaluation of thalidomide in patients with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide therapy in refractory solid tumour patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide-induced neuropathy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide neuropathy in patients treated for metastatic prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide-induced toxic epidermal necrolysis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide-associated hepatitis: a case report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thalidomide treatment in multiple myeloma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of plasma cell dyscrasias with thalidomide and its derivatives
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916308-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(04)16308-3
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
PubMed ID
15172781
1 reference
stated in
Europe PubMed Central
PubMed ID
15172781
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15172781%20AND%20SRC:MED&resulttype=core&format=json
retrieved
29 December 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit